{
  "id": "5c72a9147c78d6947100006e",
  "type": "list",
  "question": "Which drugs are included in the Lonsurf pill?",
  "ideal_answer": "Lunsurf pill includes trifluridine and tipiracil. It is a novel form of chemotherapy for metastatic colorectal cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28315543",
    "http://www.ncbi.nlm.nih.gov/pubmed/29177842",
    "http://www.ncbi.nlm.nih.gov/pubmed/27431756",
    "http://www.ncbi.nlm.nih.gov/pubmed/26609205",
    "http://www.ncbi.nlm.nih.gov/pubmed/30445951",
    "http://www.ncbi.nlm.nih.gov/pubmed/26197742",
    "http://www.ncbi.nlm.nih.gov/pubmed/30350179",
    "http://www.ncbi.nlm.nih.gov/pubmed/27568360"
  ],
  "snippets": [
    {
      "text": "The National Institute for Health and Care Excellence (NICE) invited Servier, the company manufacturing trifluridine and tipiracil (T/T; trade name: Lonsurf\u00ae), to submit evidence for the clinical and cost effectiveness of T/T compared with best supportive care (BSC) for metastatic colorectal cancer (third-line or later). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29177842",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Trifluridine/tipiracil (FTD/TPI; TAS-102, Lonsurf\u00ae), a novel form of chemotherapy for metastatic colorectal cancer (mCRC), has shown clinical benefit in the global, phase III RECOURSE trial, regardless of patient age. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30350179",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Trifluridine/tipiracil (TAS-102, Lonsurf\u00ae), a novel oral anti-tumor agent combining an anti-neoplastic thymidine-based nucleoside analogue (trifluridine, FTD) with a thymidine phosphorylase inhibitor (tipiracil hydrochloride, TPI) presents a new treatment option for metastatic colorectal cancer (mCRC) patients refractory or intolerant to standard therapies. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30445951",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These AEs may affect patient adherence, particularly with completely oral regimens, such as trifluridine/tipiracil (TAS-102, Lonsurf\u00ae), an antimetabolite agent for patients with mCRC refractory or intolerant to standard therapies.\u2029",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28315543",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trifluridine/tipiracil has recently been approved for the treatment of adult patients with metastatic colorectal cancer (mCRC) who are refractory to or are not considered candidates for, current standard chemotherapy and biological therapy in the EU and USA and in unresectable advanced or recurrent CRC in Japan. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27568360",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "TAS-102 (Lonsurf) is an oral fluoropyrimidine that is formed by the combination of 2 active drugs: trifluridine (a nucleoside analog) and tipiracil hydrochloride (a thymidine phosphorylase inhibitor).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27431756",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Evolocumab (Repatha) for patients with hypercholesterolemia whose condition has not been controlled by statins and other therapies; trifluridine/tipiracil (Lonsurf) for metastatic colorectal cancer; and blood coagulation factor VIII (Nuwiq) for adults and children with hemophilia A.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26609205",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In May 2014, tablets containing both trifluridine and tipiracil hydrochloride (Lonsurf\u00ae tablets) were launched in Japan ahead of other countries, for the treatment of advanced/relapsed unresectable colorectal cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26197742",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Initial Evaluation of the Efficacy and Safety of Tablets Containing Trifluridine and Tipiracil Hydrochloride--Safety Measures Devised by a Multidisciplinary Team Including a Pharmaceutical Outpatient Clinic.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26197742",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [],
  "exact_answer": "trifluridine, tipiracil"
}